FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumour has EGFR or ALK gene abnormalities.
Bristol-Myers Squibb Foundation joins White House Cancer Moonshot
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Foundation joins the White House Cancer Moonshot initiative through its commitment to addressing health disparities in cancer care. In response to the Cancer Moonshot, the Foundation is committing $25 million in new funding to grantee partners to expand the current scope of community-based resources and survivorship support programs to underserved populations in the U.S.
Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines.
Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Europe 2017, a collaborative drug discovery initiative for universities and research institutes in Europe. TaNeDS programme was launched in Japan in 2011 to help discover new lines of research through open innovation.
Merck announces recipients of third annual €1 million 'Grant for Oncology Innovation' award
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the recipients of the 2016 Grant for Oncology Innovation (GOI), who will share a €1 million grant to progress their respective research initiatives. The winners were formally awarded yesterday evening at an award presentation coinciding with the 2016 annual European Society of Medical Oncology (ESMO) Congress in Copenhagen, Denmark.
AstraZeneca enters agreement with Cilag GmbH International to divest rights to Rhinocort Aqua outside the US
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US. Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of the nasal lining).
FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib). The latest BTD was granted for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
More Pharma News ...
- Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
- Boehringer Ingelheim and SARAH CANNON Research Institute launch strategic collaboration to develop novel immune-oncology therapies
- Amgen and Arrowhead Pharmaceuticals announce two cardiovascular collaborations
- Sandoz invites young entrepreneurs to enter #SandozHACk, a global competition to help solve healthcare access challenges
- Bristol-Myers Squibb and Nektar Therapeutics announce oncology clinical collaboration to evaluate the combination of Opdivo (nivolumab) and NKTR-214
- Pfizer decides remaining one company best positions company to maximize future value creation
- Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs